MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 48, 2015, Pages 14924-14929

  Gasparini, Pierluigi ^a   Cascione, Luciano ^b   Landi, Lorenza ^c   Carasi, Stefania ^a   Lovat, Francesca ^a   Tibaldi, Carmelo ^c   Alì, Greta ^d   D'Incecco, Armida ^c   Minuti, Gabriele ^c   Chella, Antonio ^d   Fontanini, Gabriella ^d   Fassan, Matteo ^e   Cappuzzo, Federico ^c   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

EGFR; EML4 ALK; KRAS; Lung cancer; MicroRNAs

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; K RAS PROTEIN; MICRORNA; MICRORNA 1253; MICRORNA 26A 5P; MICRORNA 504; MICROTUBULE ASSOCIATED PROTEIN 4; MUTANT PROTEIN; PARAFFIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE; RNA;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CLASSIFIER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHINODERM; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL PREDICTION; ANIMAL; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CLASSIFICATION; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; RAT; SURVIVAL RATE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84948697950     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520329112     Document Type: Article

References (24)

1. Davidson MR, Gazdar AF, Clarke BE (2013) The pivotal role of pathology in the management of lung cancer. J Thorac Dis 5(Suppl 5):S463-S478.
2. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK (2014) Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer 14(8):535-546.
3. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28(36):5311-5320.
4. Li T, Kung HJ, Mack PC, Gandara DR (2013) Genotyping and genomic profiling of nonsmallcell lung cancer: Implications for current and future therapies. J Clin Oncol 31(8):1039-1049.
5. Volinia S, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257-2261.
6. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704-714.
7. Garofalo M, et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6):498-509.
8. Garofalo M, et al. (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74-82.
9. Heneghan HM, Miller N, Kerin MJ (2010) MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 10(5):543-550.
10. Hothorn T, Hornik K, Zeileis A (2006) Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 15(3):651-674.
11. Zelleis A, Hothorn T, Hornik K (2008) Model-based recursive partitioning. J Comput Graph Stat 17(2):492-514.
12. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-550.
13. Levy MA, Lovly CM, Pao W (2012) Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Res 22(11):2101-2108.
14. Acunzo M, et al. (2012) miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 31(5):634-642.
15. Camidge DR, et al. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13(10):1011-1019.
16. Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: From discovery to therapy in record time. Cancer Cell 18(6):548-551.
17. Soda M, et al. (2007) Identification of the transforming EML4-ALK fusion gene in nonsmallcell lung cancer. Nature 448(7153):561-566.
18. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19:716-723.
19. Gönen M H G (2005) Concordance probability and discriminatory power in proportional hazards regression. Biometrika 92(4):965-970.
20. Harrell FE (2001) Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. (Springer, New York).
21. Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC curves. Biometrics 61(1):92-105.
22. Kwak EL, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693-1703.
23. Boldrini L, et al. (2009) Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncol Rep 22(4):683-691.
24. Querings S, et al. (2011) Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6(5):e19601.